Lianxin Medical Files IPO Prospectus in September 2025
NeuroXess
Invasive Brain-Computer Interface Developer
DeepWise
Developer of Artificial Intelligence Medical Imaging Diagnosis System
CF PharmTech
Full-series Product Developer for the Respiratory System
Business Progress
On September 11, NeuroXess published research results on the realization of long-term stable decoding with a universal implantable flexible brain-computer interface.
The prestigious international journal *Advanced Science* has published a significant research achievement jointly completed by the Shanghai Institute of Microsystem and Information Technology of the Chinese Academy of Sciences, NeuroXess, and Huashan Hospital Affiliated with Fudan University — a universal implantable flexible brain-computer interface system with broad compatibility. Equipped with a brain-computer operating system, this system can flexibly control various physical and digital devices through brain signals, achieving precise mind control over more than 20 types of digital/physical devices. After similar training durations, its information transmission rate (BPS) is comparable to that of Neuralink's subjects led by Elon Musk. Notably, this marks the first long-term implant clinical trial study conducted by a team in China using MEMS-based high-throughput, high-resolution flexible brain-computer interfaces, laying an important foundation for the clinical translation of high-throughput flexible brain-computer interfaces.
On September 15, Antorna Bio's ART104 treatment for ALGS completed the first patient dosing in the IIT clinical trial.
On September 15, Arnatar Therapeutics, a biotechnology company focused on developing RNA-targeted therapies for severe diseases with unmet medical needs, announced that the first patient has been dosed in an investigator-initiated trial (IIT) of its drug ART104, with no discomfort reported throughout the process. The first follow-up visit after dosing has been completed, and no drug-related adverse effects were identified during the evaluation, indicating good safety. ART104 is a world-first antisense oligonucleotide (ASO) drug designed to treat Alagille syndrome (ALGS) at its genetic root cause. This IIT study is being led by Professor Jian-she Wang from the Children's Hospital of Fudan University, a global expert in ALGS research and treatment.
On September 24, Deepwise's multimodal MRI research achieved early and precise evaluation of AIS.
Recently, a research team led by Professor Wang Yunling from the First Affiliated Hospital of Xinjiang Medical University, in collaboration with Deepwise, published an innovative research achievement focused on clinical diagnosis of stroke, which was included in "Academic Radiology." The study successfully predicted neurological deficits and assessed the severity in patients with acute ischemic stroke (AIS) by utilizing a Cross-attention Vision Transformer (ViT) model combined with multimodal MRI data, providing more objective imaging and AI-based evaluation support for clinical treatment plans.
The Hong Kong public offering of CF PharmTech (02652.HK) began on September 26.
CF PharmTech (02652.HK) announced that the company plans to offer 41,198,000 H shares globally, including 4,120,000 shares for the Hong Kong offering and 37,078,000 shares for international placement. The offering will take place from September 26 to October 2, 2025. The issue price will be HK$14.75 per share, with each trading unit consisting of 500 shares. CITIC Securities and CMB International are the joint sponsors. It is expected that the shares will begin trading on the Stock Exchange on October 8, 2025.
On September 28, Deepwise's Condo Robot successfully "started work" at Lishui Central Hospital.
Lishui Central Hospital Successfully Hosts the Launch Ceremony of the Endoscopic Surgical Robot. The domestically produced endoscopic surgical robot independently developed by the company, Condo Robot® Laparoscopic Endoscope Surgery System (Model: SR2000), has been officially put into use in the hospital. This also marks an important step for Lishui City in the application field of high-end medical equipment.
Shanghai Pharma Cloud Health Wins PharmaX "Digital Intelligence Pharmacy Innovation Award", Leading Industry Development with Innovation
New Alliance Capital was founded in August 2008 and is a fund management company focused on private equity and venture capital investments. New Alliance Capital currently manages multiple funds with a total scale of managed assets exceeding 15 billion RMB.
The main investment directions of Lianxin Capital includeInformation technology, healthcare, new energy, and high-end manufacturing fields,Covering all stages, including early stage, growth stage, and maturity stage. It has completed over 160 investments to date, among which nearly 40 companies have gone public or been listed in China and overseas, nurturing a group of industry leaders.
The principle of "growing together with great enterprises," coupled with profound industry experience, has made Lianxin Capital the most favored partner for both investors and invested companies.
